News

Nabriva in antibiotics deal with Forest
Enlarge image

BusinessAustria

Nabriva in antibiotics deal with Forest

04.06.2012 - Austrian biotech Nabriva Therapeutics AG has partnered with Forest Laboratories Inc. to develop its antibiotic BC-3781.

Vienna - As part of the deal, Forest will have the exclusive right to acquire Nabriva for the next 12 months. Nabriva will receive US$25m. Forest will also fund and help develop BC-3781 during the period.  BC-3781 belongs to a novel class of antibiotics, the pleuromutilins. It is designed to treat severe and drug resistant infections including MRSA, penicillin-resistant Streptococcus pneumonia, Legionella pneumophila, which causes Legionnaires' disease, and Chlamydophila pneumoniae, a major cause of pneumonia. 

BC-3781 has potential in both intravenous and oral formulations and the cooperating companies plan to advance it into Phase III testing early next year. Forest said the oral formulation provides an opportunity to treat patients after they leave the hospital and would complement its Teflaro ceftaroline, a cephalosporin antibiotic available only as an intravenous drug. 

Nabriva is based in Vienna, and in 2011 it reported positive mid-stage trial results from a Phase IIb  study that evaluated BC-3781 as a treatment for acute bacterial and skin structure infections. 

http://www.european-biotechnology-news.com/news/news/2012-02/nabriva-in-antibiotics-deal-with-forest.html

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Stock MarketsEUFranceUKNorwaySweden

09.04.2015 The European public markets remain highly attractive for biotech companies. Twice as many companies went public in the first quarter of 2015 than during the same period last year.

FinancingAustriaUKSwitzerlandGermany

08.04.2015 To bring its lead product of a new class of antimicrobials to phase 3 trials, Nabriva Therapeutics has completed a US$120m Series B financing.

Research & DevelopmentNetherlands

07.04.2015 Gene therapy is attracting more and more big pharma companies. Now, Bristol-Myers Squibb has forged a US$1bn collaboration with Dutch uniQure, also picking up a 4.9% share in the company.

Stock MarketsFrance

02.04.2015 Sensorion is the latest French biotech to go public, following a spate of IPOs on Paris Euronext. The biopharma plans for a €12m IPO to finance its pipeline of inner ear disease drugs.

M&AIreland

31.03.2015 In its aim to expand its drug portfolio in orphan disease products, Horizon Pharma has acquired US company Hyperion Therapeutics for US$1.1bn in cash. The takeover entitles the UK biopharma to all of Hyperion’s common stock.

BusinessGermany

31.03.2015 Merck Serono has forged a US$941m (€876m) deal with US Intrexon for the development and commercialisation of CAR-T therapies. The new CAR-T projects are set to strengthen their R&D technology portfolio in immuno-oncology.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MORPHOSYS64.50 EUR6.19%
  • CO.DON3.10 EUR4.38%
  • 4SC1.23 EUR4.24%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • CYTOS1.24 CHF-3.12%
  • SANTHERA97.60 CHF-2.16%

TOP

  • 4SC1.23 EUR78.3%
  • MEDIGENE13.14 EUR67.0%
  • FORMYCON31.20 EUR31.9%

FLOP

  • THERAMETRICS0.07 CHF-12.5%
  • EPIGENOMICS5.32 EUR-10.4%
  • BB BIOTECH290.10 EUR-8.4%

TOP

  • SANTHERA97.60 CHF2649.3%
  • CYTOS1.24 CHF629.4%
  • FORMYCON31.20 EUR339.4%

FLOP

  • MOLOGEN5.11 EUR-52.7%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.58 EUR-20.9%

No liability assumed, Date: 20.04.2015